Reluscovtogene ralaplasmid clinical trials
Also written INO-4800.
How each study uses reluscovtogene ralaplasmid is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- INO-4800
- 4
Studies by the year they started
4 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2020 | 3 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Inovio Pharmaceuticals (3) · International Vaccine Institute (1)
Studies
Open first, then newest update. How each study uses reluscovtogene ralaplasmid is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 ExposureTerminatedPhase 2/3Inovio PharmaceuticalsNCT04642638Written as INO-4800How we know
- Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy VolunteersWithdrawnPhase 1Inovio PharmaceuticalsNCT05430958Written as INO-4800How we know
- Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19CompletedPhase 1/2International Vaccine InstituteNCT04447781Written as INO-4800How we know
- Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy VolunteersCompletedPhase 1Inovio PharmaceuticalsNCT04336410Written as INO-4800How we know
Codes
What other systems call reluscovtogene ralaplasmid · ClinicalTrials.gg INT001304
- MeSH (NLM) C000706171reluscovtogene ralaplasmidOne source NLM
- UNII (FDA) 5Y0I0UU2ITRELUSCOVTOGENE RALAPLASMIDConfirmed FDA, NLM
- NCI Thesaurus C172734Reluscovtogene RalaplasmidOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000706171 | reluscovtogene ralaplasmid | One source NLM |
| UNII (FDA) | 5Y0I0UU2IT | RELUSCOVTOGENE RALAPLASMID | Confirmed FDA, NLM |
| NCI Thesaurus | C172734 | Reluscovtogene Ralaplasmid | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.